Related Experiment Video

Updated: Jun 23, 2026

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Potential for molecularly targeted therapy against epidermal growth factor receptor ligands

Shingo Miyamoto1, Tatsuya Fukami, Hiroshi Yagi

  • 1Department of Biochemistry, Faculty of Medicine, Fukuoka University, Jonan-ku, Fukuoka, 814-0180, Japan. smiya@cis.fukuoka-u.ac.jp

Anticancer Research
|May 6, 2009
PubMed

Insights

Targeting epidermal growth factor receptor (EGFR) ligands, like HB-EGF and amphiregulin, shows promise for overcoming resistance to EGFR antagonists in cancer therapy.

Area of Science:

  • Cancer cell biology
  • Molecularly targeted cancer therapies
  • Epithelial malignancies

Background:

  • Decades of research in cancer cell biology have led to ErbB receptor-targeted therapies.
  • Epidermal growth factor receptor (EGFR) signaling inhibition is a key strategy in molecularly targeted cancer therapy.
  • EGFR antagonists show promise but face challenges due to acquired resistance.

Purpose of the Study:

  • To review EGFR signaling inhibition strategies.
  • To highlight the role of EGFR ligands in acquired resistance to EGFR antagonists.
  • To discuss targeting EGFR ligands like HB-EGF and amphiregulin as a therapeutic approach.

Main Methods:

  • Review of existing research on EGFR signaling and targeted therapies.
  • Analysis of molecular mechanisms underlying resistance to EGFR antagonists.
  • Discussion of therapeutic strategies targeting EGFR ligands.

Main Results:

  • Aberrant enhancement of EGFR ligand expression is a potential mechanism for acquired resistance to EGFR antagonists.
  • EGFR ligands are emerging as significant targets for cancer therapy.
  • Specific ligands like HB-EGF and amphiregulin are discussed as therapeutic targets.

Conclusions:

  • Targeting EGFR ligands presents a promising strategy to overcome resistance to EGFR antagonists.
  • Further research into EGFR ligand-directed therapies, including HB-EGF and amphiregulin, is warranted.
  • This approach offers potential for improved clinical outcomes in epithelial malignancies.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...